MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Stevanato Group SpA

Slēgts

SektorsVeselības aprūpe

20.15 -3.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.69

Max

21.01

Galvenie mērījumi

By Trading Economics

Ienākumi

-86M

9.8M

Pārdošana

53M

331M

P/E

Sektora vidējais

43.447

63.778

EPS

0.205

Dividenžu ienesīgums

0.28

Peļņas marža

2.966

Darbinieki

5,521

EBITDA

-36M

68M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+19.84% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.28%

2.39%

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

595M

5.5B

Iepriekšējā atvēršanas cena

23.83

Iepriekšējā slēgšanas cena

20.15

Ziņu noskaņojums

By Acuity

50%

50%

166 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Stevanato Group SpA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. apr. 23:04 UTC

Top Ziņas

JPMorgan Raises Risk of U.S., Global Recession to 60%

2025. g. 3. apr. 22:40 UTC

Galvenie tirgus virzītāji

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

2025. g. 3. apr. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

2025. g. 3. apr. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

2025. g. 3. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

2025. g. 3. apr. 23:41 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

2025. g. 3. apr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 21:43 UTC

Top Ziņas
Peļņas

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. apr. 20:43 UTC

Tirgus saruna

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

2025. g. 3. apr. 20:34 UTC

Top Ziņas

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

2025. g. 3. apr. 20:23 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

2025. g. 3. apr. 19:21 UTC

Tirgus saruna

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

2025. g. 3. apr. 19:15 UTC

Tirgus saruna

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Gold Drops In Tariff Fallout -- Market Talk

2025. g. 3. apr. 18:39 UTC

Tirgus saruna

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

2025. g. 3. apr. 18:38 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 18:30 UTC

Top Ziņas

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

2025. g. 3. apr. 18:20 UTC

Tirgus saruna

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

2025. g. 3. apr. 18:18 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:17 UTC

Tirgus saruna

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

2025. g. 3. apr. 18:04 UTC

Tirgus saruna

US Sees More Job Openings in Construction, Transportation -- Market Talk

2025. g. 3. apr. 17:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Stevanato Group SpA Prognoze

Cenas mērķis

By TipRanks

19.84% augšup

Prognoze 12 mēnešiem

Vidējais 25.13 USD  19.84%

Augstākais 28 USD

Zemākais 23 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Stevanato Group SpA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

3

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

20.07 / 20.46Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

166 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.